MICHAEL G ATIEH
CIK 1072501 · EVP, CFO, & CBO, Treasurer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.55M
Companies
7
Total Filings
64
Lifetime Open-Market Net
-$7.82M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMTX | Director | — | $8.73 | — | $0 | 1 | 2026-06-18 |
| CB | Director | 40,014 | $363.50 | $14.55M | -$2.56M | 24 | 2026-05-26 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 8,671 | $11.17 | $96.9K | $0 | 4 | 2023-01-04 |
| ECOR | Director | — | $6.09 | — | $0 | 3 | 2021-06-15 |
| IVERIC bio, Inc. (OPHT) Delisted | EVP, CFO, & CBO, Treasurer | 367 | — | — | -$9.4K | 3 | 2016-01-05 |
| Chubb Ltd (ACE) Delisted | Director | 38,618 | — | — | -$1.85M | 14 | 2015-05-26 |
| OSI PHARMACEUTICALS INC (OSIP) Delisted | Exec. VP & CFO | 32,447 | — | — | -$3.40M | 10 | 2008-12-16 |
Recent Filings · Page 2 of 7
64 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-17 | CB | Mixed | +479 | -$63.3K | EDGAR |
| 2023-08-14 | CB | Sell (S) | −750 | -$156.3K | EDGAR |
| 2023-07-28 | CB | Notice (144) | −750 | -$156.3K | EDGAR |
| 2023-05-19 | CB | Mixed | +722 | -$46.4K | EDGAR |
| 2023-01-04 | Oyster Point Pharma, Inc. (OYST) Delisted | Mixed | −26,734 | $0 | EDGAR |
| 2022-06-08 | Oyster Point Pharma, Inc. (OYST) Delisted | Grant (A) | +3,573 | $0 | EDGAR |
| 2022-05-23 | CB | Mixed | +161 | -$157.0K | EDGAR |
| 2021-08-20 | CB | Sell (S) | −2,944 | -$548.2K | EDGAR |
| 2021-06-15 | ECOR | Grant (A) | — | $0 | EDGAR |
| 2021-06-09 | Oyster Point Pharma, Inc. (OYST) Delisted | Grant (A) | +3,466 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.